Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 18/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30703606 | 1.00 | IRAK4 (0.42) | IRAK4IRAK1GSK3BDYRK1A | |
| SCHEMBL20090304 | 1.00 | IRAK4 (0.42) | IRAK4IRAK1GSK3BDYRK1A | |
| SCHEMBL20090317 | 1.00 | IRAK4 (0.42) | IRAK4IRAK1GSK3BDYRK1A | |
| SCHEMBL20090302 | 0.94 | IRAK4 (0.46) | IRAK4IRAK1GSK3BDYRK1A | |
| SCHEMBL30703608 | 0.94 | IRAK4 (0.46) | IRAK4IRAK1GSK3BDYRK1A | |
| SCHEMBL20161141 | 0.94 | IRAK4 (0.46) | IRAK4IRAK1GSK3BDYRK1A | |
| SCHEMBL24780933 | 0.90 | IRAK4 (0.40) | IRAK4IRAK1 | |
| SCHEMBL20090319 | 0.90 | IRAK4 (0.40) | IRAK4IRAK1 | |
| SCHEMBL30259930 | 0.90 | IRAK4 (0.40) | IRAK4IRAK1 | |
| SCHEMBL20161246 | 0.86 | IRAK4 (0.44) | IRAK4IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532470-B1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-10941140-B2 | IRAK inhibitors and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190300518-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | Rigal Pharmaceuticals, Inc. (US) | 2019-10-03 | — | — | US | disclosed |
| WO-2018089199-A1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941140-B2 | IRAK inhibitors and method for making and using | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885IRAK1 1/4885GSK3B 358/4885 |
| US-20190300518-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885IRAK1 1/4885GSK3B 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.